Despite some conflicting results [188,189,190], a recent meta-analysis revealed that plasma visfatin levels are significantly increased in subjects presenting overweight/obesity, IR, metabolic syndrome and cardiovascular diseases [191], with visfatin expression seeming to be modulated by some insulin-sensitising agents. This evidence concerns the gene NAMPT and cardiovascular disorder.